Megna Michael R 4

Accession 0001415889-25-023564

CIK 0001730430other

View on SEC.gov Company Profile

Filed

Sep 2, 8:00 PM ET

Accepted

Sep 3, 4:56 PM ET

Size

31.9 KB

Accession

0001415889-25-023564

Insider Transaction Report

Form 4

Period: 2025-09-01

Kiniksa Pharmaceuticals International, plcKNSA

Megna Michael R

CHIEF ACCOUNTING OFFICER

Transactions

Exercise/Conversion
Class A Ordinary Share
2025-09-01+3,933→ 41,894 total
Tax Payment
Class A Ordinary Share
2025-09-01$33.49/sh−4,282$143,404→ 37,612 total
Tax Payment
Class A Ordinary Share
2025-09-02$34.28/sh−375$12,855→ 38,011 total
Exercise/Conversion
Restricted Share Unit
2025-09-02−774→ 0 total
→ Class A Ordinary Share (774 underlying)
Exercise/Conversion
Class A Ordinary Share
2025-09-01+2,557→ 37,961 total
Sale
Class A Ordinary Share
2025-09-03$34.84/sh−11,000$383,240→ 38,011 total
Exercise/Conversion
Class A Ordinary Share
2025-09-03$17.92/sh+11,000$197,120→ 49,011 total
Exercise/Conversion
Restricted Share Unit
2025-09-01−2,363→ 7,087 total
→ Class A Ordinary Share (2,363 underlying)
Exercise/Conversion
Restricted Share Unit
2025-09-01−3,933→ 3,932 total
→ Class A Ordinary Share (3,933 underlying)
Exercise/Conversion
Share Option
2025-09-03−11,000→ 0 total
Exercise: $17.92Exp: 2029-03-03→ Class A Ordinary Share (11,000 underlying)
Exercise/Conversion
Class A Ordinary Share
2025-09-01+2,363→ 35,404 total
Award
Restricted Share Unit
2025-09-01+10,575→ 10,575 total
→ Class A Ordinary Share (10,575 underlying)
Award
Share Option
2025-09-01+21,150→ 21,150 total
Exercise: $33.49Exp: 2035-08-31→ Class A Ordinary Share (21,150 underlying)
Exercise/Conversion
Restricted Share Unit
2025-09-01−2,557→ 5,115 total
→ Class A Ordinary Share (2,557 underlying)
Exercise/Conversion
Class A Ordinary Share
2025-09-02+774→ 38,386 total

Footnotes (10)

[F1]Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer.
[F10]The option is fully vested and Exercisable.
[F2]This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on July 24, 2024.
[F3]This transaction was executed in multiple trades through a broker-dealer at prices ranging between $34.80 and $35.005. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.
[F4]The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2025.
[F5]The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is September 1, 2025.
[F6]The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the grant date, September 1, 2024.
[F7]The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2023.
[F8]The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2022.
[F9]The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 2, 2021.

Documents

1 file

4
form4-09032025_080915.xmlPrimary

Issuer

Kiniksa Pharmaceuticals International, plc

CIK 0001730430

→

Entity typeother

Related Parties

filerCIK 0001464583

Filing Metadata

Form type: 4
Filed: Sep 2, 8:00 PM ET
Accepted: Sep 3, 4:56 PM ET
Size: 31.9 KB

View on SEC.gov